The MMAE‐conjugated anti‐CD30 ADC BV has shown exciting response rates in both relapsed/refractory HL and ALCL (Chen et al., 2016; Pro et al., 2012). The gene discussed is TNFRSF8; the disease is anaplastic large cell lymphoma.